MFG
CTMX icon

Magnus Financial Group’s CytomX Therapeutics CTMX Stock Holding History

Magnus Financial Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,000
Closed -$30.2K – 277
2023
Q1 		$30.2K Hold
20,000
– – ﹤0.01% 273
2022
Q4 		$32K Hold
20,000
– – 0.01% 263
2022
Q3 		$29K Buy
+20,000
New +$30.8K 0.01% 249

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Magnus Financial Group's CTMX Position: Q2 2023 in Review

Magnus Financial Group sold out of CytomX Therapeutics (CTMX) in Q2 2023, closing a stake of 20,000 shares — an estimated $30.2K sold.

Magnus Financial Group first reported a position in CTMX in Q3 2022 and held it in 3 quarters. The position peaked at $32K in Q4 2022. 67 funds tracked by Wall St. Rank hold CTMX as of Q2 2023.

  • Magnus Financial Group reported no remaining CytomX Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Magnus Financial Group sold 20,000 CytomX Therapeutics shares in Q2 2023, an estimated $30.2K.
  • Magnus Financial Group first reported a position in CytomX Therapeutics in Q3 2022 and held it in 3 quarters.
  • Magnus Financial Group's CytomX Therapeutics position peaked at $32K in Q4 2022.
  • 67 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2023.

Based on Magnus Financial Group's 13F filing for Q2 2023, filed 19 Jul 2023.